Taesik Gwag1,2, Eric Ma1,2, Changcheng Zhou3, Shuxia Wang1,2. 1. Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA. 2. Lexington VA Medical Center, Lexington, Kentucky, USA. 3. Division of Biomedical Sciences, School of Medicine, University of California, Riverside, California, USA.
Abstract
BACKGROUND & AIMS: With the epidemic burden of obesity and metabolic diseases, nonalcoholic fatty liver disease (NAFLD) including steatohepatitis (NASH) has become the most common chronic liver disease in the western world. NASH may progress to cirrhosis and hepatocellular carcinoma. Currently, no treatment is available for NASH. Therefore, finding a therapy for NAFLD/NASH is in urgent need. Previously we have demonstrated that mice lacking CD47 or its ligand thrombospondin1 (TSP1) are protected from obesity-associated NALFD. This suggests that CD47 blockade might be a novel treatment for obesity-associated metabolic disease. Thus, in this study, the therapeutic potential of an anti-CD47 antibody in NAFLD progression was determined. METHODS: Both diet-induced NASH mouse model and human NASH organoid model were utilized in this study. NASH was induced in mice by feeding with diet enriched with fat, fructose and cholesterol (AMLN diet) for 20 weeks and then treated with anti-CD47 antibody or control IgG for 4 weeks. Body weight, body composition and liver phenotype were analysed. RESULTS: We found that anti-CD47 antibody treatment did not affect mice body weight, fat mass or liver steatosis. However, liver immune cell infiltration, inflammation and fibrosis were significantly reduced by anti-CD47 antibody treatment. In vitro data further showed that CD47 blockade prevented hepatic stellate cell activation and NASH progression in a human NASH organoid model. CONCLUSION: Collectively, these data suggest that anti-CD47 antibody might be a new therapeutic option for obesity-associated NASH and liver fibrosis.
BACKGROUND & AIMS: With the epidemic burden of obesity and metabolic diseases, nonalcoholic fatty liver disease (NAFLD) including steatohepatitis (NASH) has become the most common chronic liver disease in the western world. NASH may progress to cirrhosis and hepatocellular carcinoma. Currently, no treatment is available for NASH. Therefore, finding a therapy for NAFLD/NASH is in urgent need. Previously we have demonstrated that mice lacking CD47 or its ligand thrombospondin1 (TSP1) are protected from obesity-associated NALFD. This suggests that CD47 blockade might be a novel treatment for obesity-associated metabolic disease. Thus, in this study, the therapeutic potential of an anti-CD47 antibody in NAFLD progression was determined. METHODS: Both diet-induced NASH mouse model and human NASH organoid model were utilized in this study. NASH was induced in mice by feeding with diet enriched with fat, fructose and cholesterol (AMLN diet) for 20 weeks and then treated with anti-CD47 antibody or control IgG for 4 weeks. Body weight, body composition and liver phenotype were analysed. RESULTS: We found that anti-CD47 antibody treatment did not affect mice body weight, fat mass or liver steatosis. However, liver immune cell infiltration, inflammation and fibrosis were significantly reduced by anti-CD47 antibody treatment. In vitro data further showed that CD47 blockade prevented hepatic stellate cell activation and NASH progression in a human NASH organoid model. CONCLUSION: Collectively, these data suggest that anti-CD47 antibody might be a new therapeutic option for obesity-associated NASH and liver fibrosis.
Authors: Oyekoya T Ayonrinde; Wendy H Oddy; Leon A Adams; Trevor A Mori; Lawrence J Beilin; Nicholas de Klerk; John K Olynyk Journal: J Hepatol Date: 2017-06-12 Impact factor: 25.083
Authors: Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman Journal: Cell Date: 2009-07-23 Impact factor: 41.582
Authors: Oliver Krenkel; Tobias Puengel; Olivier Govaere; Ali T Abdallah; Jana C Mossanen; Marlene Kohlhepp; Anke Liepelt; Eric Lefebvre; Tom Luedde; Claus Hellerbrand; Ralf Weiskirchen; Thomas Longerich; Ivan G Costa; Quentin M Anstee; Christian Trautwein; Frank Tacke Journal: Hepatology Date: 2018-02-19 Impact factor: 17.425
Authors: Jeff S Isenberg; William A Frazier; Murali C Krishna; David A Wink; David D Roberts Journal: Curr Drug Targets Date: 2008-10 Impact factor: 3.465
Authors: Vincenzo Prestigiacomo; Anna Weston; Simon Messner; Franziska Lampart; Laura Suter-Dick Journal: PLoS One Date: 2017-06-30 Impact factor: 3.240